A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells

doi:10.15344/2393-8498/2017/129

Graphy

Profile

New User

New to Graphy Publications? Create an account to get started today.

Create Account For:

Registered Users

Have an account? Sign in now.

Article Menu

Journal Menu

How to Cite | Author Information | Publication History

International Journal of Gastroenterology Disorders & Therapy Volume 4 (2017), Article ID 4:IJGDT-129, 6 pages
https://doi.org/10.15344/2393-8498/2017/129

Research Article

A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells

Jie Jin¹, Zhenzhen Li², Honghua Ding² and Dadao Jing^2,*

¹Department of Gastroenterology, Branch of Shanghai General Hospital, Shanghai, China
²Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China

Corresponding Author Details: Dr. Dadao Jing, Department of Geriatrics and Gastroenterology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China; E-mail: dadaojing@126.com

Received: 17 February 2017; Accepted: 09 August 2017; Published: 11 August 2017

Citation: Jin J, Li Z, Ding H, Jing D (2017) A Potential Asset of Proteasome Inhibitor Singly or Combined with Cisplatin Provides Inhibitory Effect on Human Gastric Cancer Cells. Int J Gastroenterol Disord Ther 4: 129. doi: http://dx.doi.org/10.15344/2393-8498/2017/129

Copyright: © 2017 Jin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Backgrounds and Objective: Proteasome inhibitors are a kind of novel anti-tumor agent which can inhibit cell growth and induce apoptosis by inhibiting the function of proteasome system and impacting the degradation of proteins related to cell growth or apoptosis. The aim of the study is to explore the effect of proteasome inhibitor Z-Leu-Leu-Phe-CHO (ZLLFC) singly or combined with cisplatin on proliferation or apoptosis of humnan gastric cancer cell SGC-7901, as well as its influence on the expression level of excision repair cross complementing 1(ERCC1) mRNA.
Methods: MTT assay was used to calculate the growth inhibitory rate of human gastric cancer cell SGC- 7901. The apoptotic cell morphology was observed with electron microscopy, the apoptotic rate was analyzed by flow cytometry and by expression level of ERCC1 mRNA detected by RT-PCR.
Results: Proteasome inhibitor ZLLFC could inhibit the growth of gastric cancer cell SGC-7901. Combined application of proteasome inhibitor ZLLFC and cisplatin significantly increase the inhibitory effect on SGC-7901 cells, induced apoptosis and increased the apoptotic rate. While, the expression level of ERCC-1 mRNA in SGC-7901 cells in the combined group was significantly lower than that of the cisplatin group (p<0.01).
Conclusion: Proteasome inhibitor ZLLFC can inhibit the growth of gastric cancer cell SGC-7901. Combined application of ZLLFC and cisplatin can significantly increase the growth inhibiory effect and the apoptosis-promoting effect of gastric cancer cell SGC-7901.

Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version